Novo Nordisk’s drug stumble leaves it suddenly much slimmer
Market will never be winner takes all given that different patients will have different requirements
Novo
since
auto-detected in 401 stories
4 months ago
Novo Nordisk shares tumble as data on weight-loss drug trial disappoints
Obesity treatment CagriSema misses goal of 25% reduction in body weight
The battle over the trillion-dollar weight-loss bonanza
Novo Nordisk and Eli Lilly are making blockbuster drugs. Can they maintain their lead?
Competition will make weight-loss drugs better, cheaper and bigger
Novo Nordisk and Eli Lilly face a growing number of challengers
|← first ← previous page 5 of 5